Case Report
Outcome of Nivolumab-Induced Vogt–Koyanagi–Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy
Table 2
Treatments and outcomes in previous cases of nivolumab-induced Vogt–Koyanagi–Harada disease-like uveitis.
| Authors | Nivolumab | Initial treatment (focal) | Initial treatment (systemic) | Outcome | Second treatment | Outcome | STTA | Topical steroids | Mydriatics |
| Current case | Discontinued | Unilateral | + | + | - | Improved, but with hearing loss | PSL 40 mg | Improved hearing loss | Hwang et al. [8] | Discontinued | NR | NR | NR | PSL 1,000 mg/day | Improved | | | Minami et al. [9] | Discontinued | Bilateral | + | NR | mPSL 1,000 mg/day | Improved | | | Ushio et al. [10] | Discontinued | NR | + | NR | - | Relapse | PSL 150 mg/day | Improved | Godse et al. [11] | Discontinued | NR | NR | NR | PSL 1 mg/kg/day | Improved | | | Ng et al. [12] | Discontinued | - | - | - | - | Worsening | PSL 60 mg/day | Improved | Czichos et al. [13] | Discontinued | NR | + | + | PSL 200 mg/day | Improved | | | Mihailovic et al. [14] | Continued | NR | + | + | PSL 2 mg/kg/day | Improved, but with macular edema | Intravitreal triamcinolone 2 mg | Improved | Gambichler et al. [15] | Discontinued | NR | NR | NR | mPSL 1,000 mg/day | Improved | | | Kikuchi et al. [16] | Discontinued | Bilateral | NR | NR | - | No remission | mPSL 1,000 mg/day | Improved | Obata et al. [17] | Discontinued | NR | + | + | - | Improved | | | Fujimura et al. [18] | Continued | NR | NR | NR | mPSL 500 mg/day | Improved | | | Fujimura et al. [18] | Continued | NR | NR | NR | mPSL 500 mg/day | Improved | | | Arai et al. [19] | Continued | NR | + | + | - | Improved | | | Matsuo et al. [20] | Continued | NR | + | NR | PSL 30 mg | Improved | | |
|
|
NR: not reported; STTA: subtenon injection of triamcinolone acetonide; PSL: prednisolone; mPSL: methylprednisolone.
|